Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease caused by a variety of mutations in transcription factors, epigenetic regulators and signaling molecules. To determine how different mutant regulators establish AML subtype-specific transcriptional networks we performed a comprehensive global analysis of cis-regulatory element activity and interaction, transcription factor occupancy and gene expression patterns in purified leukemic blast cells. Here, we focussed on specific sub-groups of patients carrying mutations in genes encoding transcription factors (RUNX1, CEBPα) and signaling molecules (FTL3-ITD, RAS, NPM1). Integrated analysis of these data demonstrates that each mutant regulator establishes a specific transcriptional and signaling network unrelated to normal cells sustaining the expression of unique sets of genes required for AML growth and maintenance.
| Original language | English |
|---|---|
| Pages (from-to) | 151-162 |
| Number of pages | 12 |
| Journal | Nature Genetics |
| Volume | 51 |
| Issue number | 1 |
| Early online date | 12 Nov 2018 |
| DOIs | |
| Publication status | Published - Jan 2019 |
Fingerprint
Dive into the research topics of 'Subtype-specific regulatory network rewiring in acute myeloid leukemia'. Together they form a unique fingerprint.Equipment
-
Birmingham Environment for Academic Research (BEAR)
Facility/equipment: Equipment
Press/Media
-
Research brings personalised medicine to treat leukaemia one step closer
12/11/18
1 Media contribution
Press/Media: Press / Media
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver